Cancer cells undergo changes in metabolic and survival pathways that increase their malignancy.
Introduction
Hexokinases are a family of four isoforms that catalyze phosphorylation of glucose, making it available for utilization in glycolysis, pentose phosphate pathway, glycogenesis and hexosamine biosynthesis (Wilson, 2003) . HK2, the most active isozyme, is markedly expressed in cells characterized by a high rate of glucose consumption, such as adipose, skeletal and cardiac muscle. During the neoplastic process, metabolic changes are required to allow cell growth in conditions of fluctuating nutrient and oxygen availability (Vander Heiden & DeBerardinis, 2017) . HK2 plays a major role in this metabolic rewiring (DeWaal et al, 2018; Robey & Hay, 2006; Wang et al, 2014) , being induced by oncogenic K-Ras activation (Patra et al, 2013) or in response to (pseudo)hypoxia (Bhalla et al, 2018; Semenza, 2013) . HK2 is mainly bound to the outer mitochondrial membrane, where it can gain privileged access to newly synthesized ATP, thus increasing efficiency in glucose usage (Mathupala et al, 2009 ), while following glucose deprivation HK2 elicits autophagy by inhibiting mTORC1 (Roberts et al, 2014) .
HK2 binding to mitochondria is increased by Akt phosphorylation, a key event occurring downstream to many signalling pathways hyperactivated in tumor cells (Miyamoto et al, 2008) . Moreover, mitochondrial HK2 takes part in the protection of cancer cells from noxious stimuli through poorly defined mechanisms that include antagonizing the activity of pro-apoptotic Bcl-2 family proteins and increasing anti-oxidant defenses through pentose phosphate pathway induction (Roberts & Miyamoto, 2015) . In cancer patients, HK2 induction is related to stage progression, acquisition of invasive and metastatic capabilities and poor prognosis (Mathupala et al, 2010) . HK2 promotes neoplastic growth in glioblastoma multiforme (Wolf et al, 2011) , confers chemoresistance in epithelial ovarian cancer (Suh et al, 2014) and is required for tumor onset and maintenance in mouse models of lung and breast cancer, where its genetic ablation is therapeutic without adverse effects (Patra et al., 2013) .
Thus, HK2 constitutes a promising target for developing anti-neoplastic strategies, but the clinical use of hexokinase inhibitors is hampered by lack of specificity or side effects (Akins et al, 2018) potentially associated with glucose metabolism derangement. A possible alternative approach is detaching HK2 from mitochondria, as we and others have previously shown that this can induce opening of a mitochondrial channel, the permeability transition pore (PTP), and consequently cell death (Chiara et al, 2008; Masgras et al, 2012; Pantic et al, 2013; Roberts & Miyamoto, 2015) . However, both a detailed comprehension of the molecular mechanisms leading to cell damage and the development of a HK2-targeting tool that is operational in in vivo tumor models are required to translate this information into the groundwork for future anti-neoplastic approaches.
Here we demonstrate that in neoplastic cells HK2 localizes in MAMs, specific subdomains of interaction between mitochondria and ER. HK2 detachment from MAMs rapidly elicits a massive Ca 2+ flux into mitochondria and consequently a calpain-dependent cell death. We ignite this process with a HK2-targeting peptide composed by modular units that can be adapted to in vivo delivery, without affecting hexokinase enzymatic activity and with no adverse effects on animal models.
Results

HK2 localizes in MAMs of neoplastic cells
Dissection of sub-mitochondrial HK2 localization can provide important functional clues, as mitochondria compartmentalize specific activities in domains formed by multiprotein platforms. After confirming that HK2 is expressed in diverse tumor samples ( Fig 1A and 1B) and associates with mitochondria ( Fig 1C) , we have found that HK2 specifically localizes in MAMs by merging the fluorescence of HK2-conjugated antibodies with mitochondria-targeted YFP and ER-targeted CFP ( Fig   1D) , or with a split-GFP-based probe for ER-mitochondria contacts (SPLICS L ) ( Fig   1E-1G and Fig EV1A) . This same analysis showed that HK2 is significantly enriched in MAMs with respect to TOM20, a protein that is uniformly distributed in the outer mitochondrial membrane ( Fig   EV1B) . MAMs are dynamic structures that control the exchange between ER and mitochondria of ions and lipids, tuning complex biological processes such as ER stress, autophagy, cell death and maintenance of glucose homeostasis (Csordas et al, 2018; Prudent & McBride, 2017; Rieusset, 2018) .
A pivotal role of MAMs is the regulation of Ca 2+ fluxes from ER to mitochondria through IP 3 Rs (Filadi et al, 2017) ; thus, HK2 displacement from MAMs could affect intracellular Ca 2+ dynamics, raising the possibility that a Ca 2+ dyshomeostasis can ensue and damage neoplastic cells.
Design of a peptide that displaces HK2 form MAMs without affecting hexokinase enzymatic activity
To investigate this possibility and to generate a tool with a potential anti-tumor activity in vivo, we have conceived a HK2-targeting Cell Penetrating Peptide (CPP), dubbed HK2pep ( Fig 1H) . HK2pep is designed with a modular structure composed of: i) a N-terminal HK2 tail, which acts as the active moiety by displacing HK2 from the outer mitochondrial membrane (in the negative control, SCRpep, this HK2-specific sequence is substituted by a scrambled one); ii) a polycation stretch required for plasma membrane permeation; iii) a polyanion sequence that shields polycation charges; iv) a matrix metalloprotease 2 and 9 (MMP2/9) target sequence that links the two charged stretches. As previously observed with similar actionable CPPs (Olson et al, 2009) , the metalloprotease target sequence inhibits cell uptake of the peptide until its polycation sequence is unmasked by MMP2/9 cleavage. MMPs are highly expressed in a variety of tumor types, where they induce extracellular matrix remodeling and favor cancer cell invasiveness (Isaacson et al, 2017) . Hence, HK2pep should be preferentially activated inside neoplasms, and its subsequent entry through the plasma membrane would then lead to HK2 displacement from mitochondria and eventually cancer cell death. Moreover, HK2pep is not permeable across the endothelium of normal blood vessels, but its dimension (about 5 kDa) allows passage across the fenestrated endothelium that perfuse many cancer types.
The active moiety of HK2pep (i.e. the cleaved peptide, cl-HK2pep, Fig 1H) is indeed able to enter cells, to interact with mitochondria ( Fig EV2A) and to induce HK2 redistribution from MAMs into cytosol in less than 2 minutes ( Fig 1I and Fig EV2B) . cl-HK2pep does not perturb hexokinase enzymatic activity either on the purified enzyme ( Fig 1J) or on cell samples, where it is equally ineffective on HK2 and on the widespread isozyme HK1 ( Fig 1K and Fig EV2C) .
HK2 detachment from MAMs elicits a Ca 2+ flux into mitochondria via IP3Rs and plasma membrane that causes mitochondrial depolarization
In accord with a role played by several MAM proteins in the regulation of Ca 2+ homeostasis, cl-HK2pep prompts cycles of ER Ca 2+ release and refill (Fig 2A) and boosts cytosolic IP 3 levels ( Fig 2B) .
This IP 3 rise is prevented by pre-incubation with the IP 3 R inhibitor Xestospongin-C (Xe-C; Fig 2B) and by chelating cytosolic Ca 2+ ( Fig EV3A) , and delayed with respect to the Ca 2+ release from ER (compare Fig 2A and 2B) . These observations are consistent with cl-HK2pep eliciting a primary Ca 2+ efflux from ER that prompts a surge in cytosolic IP 3 (Rebecchi & Pentyala, 2000) , further amplifying ER Ca 2+ release via IP 3 Rs.
Mitochondria can promptly take up Ca 2+ released from ER, resulting in modulation of the activity of Krebs cycle enzymes and preventing deregulated increases in cytosolic [Ca 2+ ] (Cannino et al, 2018; Filadi et al., 2017) . cl-HK2pep treatment rapidly boosts mitochondrial [Ca 2+ ] in a stable and Xe-Csensitive way (Movie 1 and Figure 2C -2E), rising mitochondrial [Ca 2+ ] to about 50 µM ( Fig 2F) .
However, chelation of extracellular Ca 2+ only induces a transient mitochondrial [Ca 2+ ] peak of about 12 µM ( Fig 2F) , indicating that cl-HK2pep administration elicits both Ca 2+ release from ER and Ca 2+ entry through plasma membrane (Berridge et al, 2003) and that mitochondria take up Ca 2+ from both sources. HK2 targeting also prompts a sudden and massive mitochondrial depolarization ( Fig 2G and 2H, Movie 2 and Fig EV3B-EV3E) , which follows the increase in mitochondrial [Ca 2+ ] (Fig EV3F and   EV3G ). This depolarization is inhibited by chelating cytosol or extracellular Ca 2+ and by the IP 3 R inhibitor Xe-C ( Fig 2I and 2J , Movie 3 and Fig EV3H) . Therefore, the HK2-targeted peptide causes mitochondrial Ca 2+ overload as a consequence of Ca 2+ release form ER via IP 3 Rs and of Ca 2+ entry through plasma membrane.
The HK2-targeting peptide triggers calpain-dependent cell death
Overcoming the efflux and the buffering capacity of Ca 2+ in mitochondria can induce the permeability transition pore (PTP), a high conductance channel the opening of which commits cells to death (Rasola & Bernardi, 2011; Rasola & Bernardi, 2014) . PTP opening is independently inhibited by two unrelated molecules, Cyclosporin-A (CsA) and C63, but this inhibitory effect can be overwhelmed by intense stimuli of PTP induction (Bernardi et al, 2015) . We find that both CsA and C63 do not affect mitochondrial Ca 2+ uptake following cl-HK2pep treatment ( Fig 3A) , but markedly delay mitochondrial depolarization ( Fig 3B) , indicating that this occurs downstream to PTP induction.
The HK2-targeting peptide abruptly elicits cell death in all tested cancer cell models ( Fig 3C) , whereas it is poorly effective in non-transformed cell types expressing HK2 ( Fig EV4A-EV4C ). Peptide administration triggers mitochondrial depolarization in most tumor cells after 2-4 minutes, followed by phosphatidylserine exposure on the cell surface and plasma membrane rupture in less than one hour (Fig 3H) . Taken together, these data indicate that HK2 displacement from MAMs does not trigger a classical apoptotic pathway, but rather activates a cell death process relying on the Ca 2+dependent proteases calpains (Storr et al, 2011) .
The HK2-targeting peptide kills primary B-Chronic Lymphatic Leukemia cells and inhibits neoplastic growth of colon and breast cancer cells
In order to test its efficacy as a potential anti-neoplastic treatment, we studied the effect of cl-HK2pep on freshly isolated leukemia cells obtained from B-Chronic Lymphatic Leukemia (B-CLL) patients. B-CLL is the most common leukaemia form that accounts for about 40% of all adult leukemias (Fabbri & Dalla-Favera, 2016) . Although in the last years several new molecules, including anti-CD20 antibodies as well as kinase inhibitors, have become available for B-CLL therapy, the disease remains incurable and B-CLL patients usually relapse and/or become refractory. Induction of HK2 contributes to rituximab resistance (Gu et al, 2018) , and release of MMP9 increases motility of B-CLL cells (Martini et al, 2017) ; hence, B-CLL constitutes an interesting model for testing the effectiveness of HK2pep. All B-CLL patient cells that we have analyzed express HK2 ( Fig 4A) , independently of their mutation status (Table 1) , and undergo a massive mitochondrial depolarization and cell death in the first 15 minutes of cl-HK2pep treatment ( Fig 4B-4D ). These events are calpain-dependent ( Fig 4B-4D) , and in all analyzed samples HK2 targeting completely erases B-CLL cells ( Fig 4E) , whereas it is less effective in inducing death in non-neoplastic, CD19 + B cells ( Fig 4F) .
We have then evaluated the effect of targeting HK2 on solid tumors. Silencing HK2 expression hampers the ability of cancer cells to form colonies ( Fig 5A and 5B) , and HK2 targeting with both cl-HK2pep and the entire HK2pep inhibits in vitro tumorigenic growth by killing cancer cells ( Fig 5C and   5D ). Efficacy of the entire HK2pep indicates that its active moiety is released by MMP2/9 cleavage, and that this peptide can be used on in vivo neoplastic models in which HK2 and MMP2/9 are expressed ( Fig 5E and Fig EV5A) . We observe that intra-tumor injections of either cl-HK2pep or entire HK2pep significantly decrease the volume of allograft-injected colon cancer cells ( Fig 5F) , and the same result is achieved by intraperitoneal injection of entire HK2pep on both colon and breast cancer allografts ( Fig 5H and 5I) , without any tissue damage in treated animals ( Fig EV5B) .
Discussion
Our results indicate that HK2 specifically locates in MAMs, and that unhinging HK2 from MAMs swiftly elicits calpain-dependent death in cancer cells by funneling Ca 2+ into mitochondria from ER and extracellular milieu. This signalling pathway is unprecedented, even though it is consistent with emerging evidences of a role played by MAMs in the maintenance of glucose homeostasis (Rieusset, 2018) . We unveil a role of HK2 in handling intracellular Ca 2+ fluxes, which suggests that HK2 can act as a regulatory hub to integrate glucose metabolism with Ca 2+ -mediated biochemical events, spanning from physiological responses to metabolic fluctuations to death induction under stress conditions. Hence, HK2 could contribute to the orchestration of the biochemical crosstalk between ER and mitochondria, with relevant implications both in the physiology and in several pathological conditions of HK2-expressing tissues, including diabetes, ischemic damage of the heart or muscle wasting diseases, notwithstanding tumors.
HK2 shuttling to mitochondria is modulated by Akt-dependent threonine phosphorylation (Miyamoto et al., 2008) and HectH9-dependent, non-proteolytic lysine ubiquitination (Lee et al, 2019) . These data place mitochondrial localization of HK2 in a multifaceted network of regulatory events, and the functional interaction between HK2 and IP3Rs that we observe further adds to this network. A thorough dissection of the dynamic modulation of these interactions will be instrumental for the comprehension of the effects of HK2 displacement from MAMs. Importantly, non-tumor cells expressing HK2 are much more refractory to peptide toxicity than neoplastic cells. This is a promising observation under a therapeutic perspective. Nonetheless, it is necessary to understand whether MAM composition differs between tumor and non-tumor cells, and how this affects HK2 activity and localization, as well as to connect cell response to HK2pep to the pattern of calpain expression, in order to draw an exhaustive picture of the mode of peptide action and to preview its effectiveness in specific settings.
The use of CPPs as vectors for the delivery of molecules with anticancer activity constitutes an active field of investigation, even though the transfer of this approach to the clinical practice has been hampered up to now by several shortcomings, such as the lack of cell specificity and the short duration of action (Raucher & Ryu, 2015) . Here we combine several strategies to overcome these limitations.
HK2pep is an activatable peptide composed by assembled modular units that can be adapted to the specific tumor(s) to be targeted. The MMP2/9 cleavage site allows the selective activation of HK2pep where these metalloproteases are highly expressed, as in the microenvironment of several tumors, but cleavage sites for other extracellular matrix components can be envisaged and tailored to specific neoplastic types. The limited size of HK2 pep (less than 5 kDa) allows its passage through the fenestrated endothelium that characterizes many malignancies, and the rapidity of action of its cleaved form can circumvent problems connected with timing of degradation or excretion. Moreover, the absence of any inhibitory effect of HK2pep on the enzymatic activity of hexokinases minimizes the risk of non-specific damage caused by alterations of glucose metabolism at secondary sites. Hence, our approach to displace HK2 from MAMs integrates selectivity, efficacy and lack of off-target effects and could be evolved towards the development of novel anti-neoplastic strategies, conceivably in combination with other chemotherapeutic approaches that target different liabilities of neoplastic cells.
Materials and Methods
Cell culture and HK2 silencing
Human cervix carcinoma HeLa cells, human breast cancer MDA-MB-231 cells, human malignant peripheral nerve sheath tumor S462 cells, human plexiform neurofibroma PN 04.4 cells, mouse breast cancer 4T1 cells and mouse colorectal carcinoma CT26 cells, mouse macrophage RAW 264.7 cells and mouse myoblast C2C12 cells were cultured in DMEM medium (Gibco); colorectal carcinoma COLO 741 cells and B-CLL MEC1 cells were cultured in RPMI 1640 medium (Gibco); both culture media were supplemented with 10% Fetal Bovine Serum (Gibco), glutamine 2 mM (Gibco), penicillinstreptomycin (100 g/ml; Invitrogen), and were kept at 37°C in a 5% CO 2 humidified atmosphere.
HKII expression was stably interfered by infecting cells with a lentivirus carrying the following shRNAs (Sigma) against mouse HKII mRNA:
(1) CCGGCATCACCCTGCTGGTTCTAAACTCGAGTTTAGAACCAGCAGGGTGATGTTTTTG;
(2) CCGGCGGTACAGAGAAAGGAGACTTCTCGAGAAGTCTCCTTTCTCTGTACCGTTTTTG.
Scrambled shRNA (Sigma) was used as negative control. Transduced cells were selected in 1.0 µg/ml puromycin.
Histological and immunohistochemical analyses
Histological and immunohistochemical analyses were performed both on primary human samples (colorectal carcinoma, n=5; breast carcinoma, n=5; MPNST, n=5; lymph nodes deriving from B-cell chronic lymphocytic leukemia patients, n=5) and on samples derived from mouse tumor models (PN tumors; CT26 and 4T1 subcutaneous grafts in Balb/c mice). In detail, 4 µm-thick tissue sections were obtained from formalin-fixed paraffin-embedded tissue samples and representative tumor areas were selected on H&E-stained slides for immunohistochemical (IHC) analysis. IHC was performed using primary goat polyclonal anti-HK2 (sc-6521, Santa Cruz) and rabbit monoclonal anti-MPP2 (ab92536, Abcam) antibodies. Antigen retrieval was performed with heat/EDTA in the Bond-Max automated immunostainer (Leica Biosystems), as previously described .
Cell lysates and Western immunoblot analysis
Cells lysis (5x10 5 for each assay) was performed in Tris 20 mmol/l, NaCl 150 mmol/l, EDTA 2 mmol/l, EGTA 2 mmol/l, Triton X-100 0.5% supplemented with phosphatase and protease inhibitors (Sigma). Protein quantification was performed with BCA Protein Assay Kit (Thermo Scientific-Pierce). After SDS/PAGE gel electrophoresis, proteins were transferred onto nitrocellulose Hybond-C Extra membranes (Amersham, Uppsala; Sweden) and immunostained with goat polyclonal anti-HK2 (clone sc-6521, Santa Cruz), anti-GAPDH (#2118, Cell Signaling), ATP5A (ab14748, Abcam), anti-UQCRC2 (ab14745, Abcam), rabbit monoclonal anti-MMP2 (ab92536, Abcam), rabbit monoclonal anti-MMP9 (ab137867, Abcam) rabbit polyclonal and TOM20 (sc-11415, Santa Cruz) antibodies.
Peptide synthesis
HK2pep, SCRpep, cl-HK2pep and cl-SCRpep were synthesized by automatic solid phase procedures using a multiple peptide synthesizer (SyroII, MultiSynTech GmbH) on a pre-loaded Wang resin (100-200 mesh) (Novabiochem). The fluoren-9-ylmethoxycarbonyl (Fmoc) strategy was used throughout the peptide chain assembly, utilizing O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) as coupling reagent. The side-chain protected amino acid building blocks used were: Fmoc-Tyr(tert-butyl), Fmoc-Glu(tert-butyl), Fmoc-Ser(tertbutyl), Fmoc-Thr(tertbutyl), Fmoc-His(trityl), Fmoc-Asn(trityl), and Fmoc-Arg(2,2,4,6,7-pentamethyldihydrobenzofuran-5sulfonyl). Cleavage of the peptides was performed by reacting the peptidyl-resins with a mixture containing TFA/H20/thioanisole/ethanedithiol/phenol (10 ml/0.5 ml/0.5 ml/0.25 ml/750 mg) for 2.5 h. Following each coupling or deprotection step, peptidyl-resin was washed with DMF (4x3.5ml). Upon complete chain assembly, resin was washed with DCM (5x 3.5ml) and gently dried under a nitrogen flow. Resin-bound peptide was treated with an ice-cold TFA, TIS, water, thioanisole mixture (90:5:2.5:2.5 v/v/v/v, 4 ml) for 2 hours. Crude peptides were purified by a preparative reverse phase HPLC. Molecular masses of the peptide were confirmed by mass spectroscopy using a Bruker Esquire 3000+ instrument equipped with an electro-spray ionization source and a quadrupole ion trap detector (QITD). The purity of the peptides was about 95% as evaluated by analytical reverse phase HPLC.
Peptide conjugation with fluorescent dyes (ATTO) was performed by reacting peptide thiol groups with maleimide-ATTO dyes. Briefly, peptides were dissolved at a 5 mg/ml concentration in PBS buffer (pH 7.2) and 1.1 equivalents of maleimide-dye were added to the solution. Reaction was monitored by HPLC until completion, then the product isolated by preparative HPLC.
HK2pep cleavage assay
Human recombinant MMP9 (911MP, R&D) was reconstituted following manufacturer's instructions in a buffer composed by 50 mM Tris, 150 mM NaCl, 10 mM CaCl 2 , 0.05% Brij-35 (w/v) at pH 7.5 and activated with p-aminophenylmercuric acetate (Sigma). hMMP9 (20nM) was incubated for 4 hours with 1µg HK2pep in a final 100µl volume; samples were analyzed by mass/spec as described above.
Measurement of hexokinase enzymatic activity
Hexokinase enzymatic activity was measured monitoring NADPH formation at 37°C with Infinite M200 spectrophotometer (TECAN) in a buffer containing 50mM Tris, 10mM MgCl 2 , 4mM ATP, 2mM glucose, 0.1 U/mL G6PDH and 1mM NADP, pH 7.4. Experiments were carried out either using Human HK2 recombinant protein (0.5µg; HXK0703, ATGEN) or total cell lysate (20µg) were exposed for 30 min to 10 M cl-HK2pep. To discriminate between HK1 and HK2 activity in cells, samples were heated to 46°C for 30 min in order to inactivate thermo-sensitive HK2 activity.
Immunofluorescence (IF) analyses
IF experiments were carried out 24 hours after transfection with TransIT®-LT1 (Mirus) on cells fixed in 4% PFA, quenched with NH 4 Cl (0.24% in PBS) and permeabilized with 0.1% Triton X-100.
Primary antibodies (rabbit monoclonal anti-HK2, H.738.7, Thermo Scientific; mouse monoclonal anti-TOM20, sc-17764, Santa Cruz) were diluted 1:150 in blocking solution (2% BSA, 10% goat serum and 0.2% gelatin in PBS) and incubated for 90 min, at RT; AlexaFluor488/555/647-conjugated secondary antibodies (Life Technologies) were diluted 1:300 in blocking solution and incubated 45 min at RT.
Images were collected on a Leica SP5-II confocal microscope, equipped with a 100x/1.4 N.A. Plan Apochromat objective. A WLL laser was used to excite each specific dye and a HyD (Leica) was employed for signal collection. After background-subtraction, the Pearson's co-localization coefficient was calculated with the ImageJ Co-localization Analysis plugin. Displayed images were processed with the automatic ImageJ plugin Enhance image to improve signal intensity, but analyses were performed on raw, background-subtracted data. For measurements of co-localization with the split-GFP-based probe for ER-mitochondria contacts (SPLICS L ) , TOM20 and HK2 channels were background subtracted, a threshold (the mean fluorescence intensity for each cell) was imposed and the % of pixels co-localized with SPLICS L was calculated, as described . The plasmids encoding mt-YFP, mt-RFP and ER-CFP were previously described .
Mitochondrial Ca 2+ measurements
For FRET-based ER Ca 2+ measurements, cells were transfected with the ER-targeted D4ER Ca 2+ probe and mounted into an open-topped chamber in Krebs-Ringer modified buffer (mKRB, in mM: 140 NaCl, 2.8 KCl, 2 MgCl 2 , 10 HEPES, 11 glucose, pH 7.4 at 37°C) supplemented with CaCl 2 1mM;
imaging was performed with a DM6000 inverted microscope (Leica, HCX Plan Apo 40× oil objective, NA 1.25), as previously described (Fedeli et al, 2019) . Excitation light was generated every 5s by a 410nm LED (Led Engin LZ1-00UA00 LED). ImageJ was used for off-line analysis of FRET experiments. YFP and CFP images were background-subtracted and analyzed selecting specific regions of interest (ROIs) on each cell. The ratio (R) between YFP and CFP emissions was calculated for each frame.
For GCAMP6f Ca 2+ measurements, cells were transfected with a cDNA encoding mitochondrial and nuclear GCAMP6f . To perform Ca 2+ measurements, medium was replaced with mKRB buffer supplemented with 1µM CsH (Adipogen) and with 1mM CaCl 2 or 500µM EGTA.
Where indicated, specific drugs were added to the buffer and pre-incubated for 30 min with BAPTA-AM (5µM, Thermo Fisher Scientific); or 1 hour with Xestospongin C (5µM, Santa Cruz), CsA (5µM, Sigma), C63 (5µM) or PD150606 (50µM, Calbiochem). Fluorescence was recorded with an inverted microscope (Zeiss Axiovert 100, Fluar 40× oil objective, NA 1.30) in the 500-530nm range (by a bandpass filter, Chroma Technologies). Probes were sequentially excited at 475 nm and at 410 nm, respectively for 180 and 300ms, every 5s. Excitation light, produced by a monochromator (polychrome V; TILL Photonics), was filtered with a 505 nm DRLP filter (Chroma Technologies). After background subtraction, images were analyzed with ImageJ, calculating the ratio (R) between emissions generated by exciting cells at 475 and 410 nm, respectively, in specific ROIs comprising the entire mitochondrial network. [Ca 2+ ] is proportional to R.
For aequorin Ca 2+ measurements, cells were transfected with a plasmid encoding low-affinity mitochondrial matrix aequorin (mit-Aeqmut), which was reconstituted by incubating cells for 1h in mKRB, supplemented with CaCl 2 1 mM and native coelenterazine (5µM, Biotium). Measurements were performed as previously described .
IP 3 measurement assay
In order to assess changes in intracellular IP3 levels, cells were transfected with a plasmid encoding the GFP-tagged pleckstrin homology (PH) domain of PLC-δ1 (GFP-PHD). Quantification of IP 3 generation was evaluated as variations in cytosolic GFP-PHD fluorescence (F) normalized to initial cytosolic fluorescence (F0), due to the release of GFP-PHD from the plasma membrane upon PIP2 cleavage and IP3 generation (Hirose et al, 1999) . Only cells (~ 80%) in which a plasma membrane localization of GFP-PHD was evident were selected for analysis. Images were collected on a DM6000 inverted microscope (Leica, HCX Plan Apo 40× oil objective, NA 1.25). Excitation light was generated every 5 s by a 460 nm LED (Led Engin).
Measurements of mitochondrial membrane potential
Mitochondrial membrane potential was analyzed using the fluorescent potentiometric compound tetramethylrhodamine methyl ester (TMRM, 20nM; Invitrogen). Cells were incubated in mKRB or DMEM without phenol red and with CsH (1μM) to inhibit P-glycoproteins. Recordings were performed either with a fluorescence microscope (Olympus IX71 or Leica DMI600B) or with a flow cytometer (FACSCanto II, Becton Dickinson). For live microscope experiments, recordings were carried out every 30 sec using CellR software (Olympus) or LAS AF software (Leica). For flow cytometry analyses, TMRM signals are measured every 15 min and analyzed with FACSDiva software (Becton Dickinson). Movies were realized using CellR software (Olympus).
Cell viability assays
Cell viability was assessed either by cytofluorimetry or by fluorescence microscopy. Cytofluorimetric recordings of phosphatidylserine exposure on the cell surface (increased staining of FITC-conjugated Annexin-V; Roche) and loss of plasma membrane integrity (7-AAD staining; Sigma) were repeated every 15 min on a FACSCanto II instrument and analyzed with FACSDiva software. Double negative cells were considered viable. Fluorescence microscope recordings were performed with Leica DMI600B microscope and acquired with LAS AF software in the presence of Annexin V-FITC, 7-AAD and TMRM pre-incubated for 45 min. Images and movie obtained with LAS AF software were analyzed with ImageJ software.
Isolation of B lymphocytes
Cell samples that matched standard morphological and immunophenotypic criteria for B-CLL were collected from 22 therapy-free patients after obtaining informed consent according to the Declaration of Helsinki. Patient characteristics are reported in Table 1 . Cells were separated by Ficoll-Hypaque gradient centrifugation (Euroclone) and B cells were purified from the PBMCs by removing T cells with the sheep erythrocyte rosetting method (Frezzato et al, 2014) . Untreated peripheral blood B cells were isolated from the PBMCs of healthy donors by negative selection with the RosetteSep for isolation of B cells (StemCell Technologies). All samples were used when they contained ≥95% CD19 + cells, as assessed by flow cytometry.
In vitro tumorigenesis assays
For soft agar assays, cells in DMEM medium supplemented with 0.5% serum were mixed with low melting point agarose (Promega) at a final 0.6% concentration and plated on a bottom layer of DMEM with 1% LMP agarose. Fresh medium (DMEM 4% serum) was added every 3 rd day. At day 15 th colonies were stained with Crystal Violet 0.005% and analyzed with ImageJ software.
For focus forming assays, cells were seeded in standard DMEM medium with 10% FBS, which was replaced with DMEM 0.5% FBS after cells reached confluence. Treatment with peptides were performed after formation of foci; dead cells were highlighted by Trypan Blue staining. Images were acquired using a Leica DMIL LED microscope equipped with a Leica ICC50 HD camera.
In vivo tumorigenesis assays
Colon cancer CT26 cells or breast cancer 4T1 cells were allografted in Balb/c mice according to a protocol approved from Italian Health Ministry (authorization number: 547/2016-PR). Briefly, 100.000 CT26 cells or 200.000 4T1 cells were injected subcutaneously in the flank of male or female animals, respectively, in a 100 μl final volume containing 30% Matrigel (Corning). Tumors were visible under the skin after 7-9 days and measured with caliper (two major axes). Tumor volume was calculated using the formula: (a*b 2 )/2. Ultrasound inspections of representative tumors were performed using Vevo 2100 (Visualsonic, Fujifilm). Acquisitions, measurements and 3D-reconstructions of tumors were done using VevoLAB 1.7.0.7071 software. Peptides where injected as described in the text. 
